An interventional study of G-EO End-Effector Gait Trainer and Conventional Physical Therapy Treatment in Parkinson Disease and Gait Disorder, Sensorimotor, sponsored by Indiana University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Indiana University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.
Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 964th largest by enrollment of the 1,257 interventional ones that give a count, is one of 105 that started in 2022, is one of 586 with no phase, and was the 1,230th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:
The Cleveland Clinic · Sites in United States
Ages 18+
University of Colorado, Denver · Sites in United States
Ages 45–75
University of Minnesota · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, China, Ireland and 2 more countries
Ages 40–85
VA Office of Research and Development · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,650 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 226 · Phase 2 304 · Phase 3 145 · Phase 4 75
First in 1991; this study’s year is marked. 105 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 36 across the 1,257 interventional studies, 78 across the 379 observational. Of the 1,140 that completed or were terminated, 435 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
470 of 1,650 have an industry lead sponsor. The 10 most frequent:
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
Indiana University has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
137 of the studies in Parkinson Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06976268Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | 2027-08 |
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT06489483University of Texas Southwestern Medical CenterAction Regulation Behavioral | 2026-11 |
| NCT06773962TrueBinding, Inc.A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | 2026-11-28 |
| NCT06447207Colorado State UniversityOccupational Therapy Led Social Prescription for People With Parkinson Disease | 2026-11-30 |
Add all 137 to your calendar (.ics) → With an account.
Among the 1,650 studies in Parkinson Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the implementation of a novel gait rehabilitation stimulus (G-EO System) that could advance current clinical practices. The goal is to establish the safety and feasibility of gait training using the G-EO System as well as investigating the impact on mobility, function, quality of life, and participatory outcomes.
Research Design: We propose a single-blinded, randomized trial of electromechanically-assisted gait training using the G-EO System in patients with Parkinson's disease with gait disability.
Specific Aim 1 will establish the safety and feasibility of gait training using the G-EO System.
Specific Aim 2 will determine the efficacy of gait training using the G-EO System for improving mobility, function, and quality of life
Individuals diagnosed with Parkinson's disease (PD) often suffer from difficulties with gait initiation, maintaining a consistent kinematic gait pattern, and transitions between gait environments. Focused gait training that provides an environment that can emphasize motor control improvement in these deficits would be ideal for building a rehabilitative foundation for gait recovery for individuals with PD.
One approach that has been used to maintain and restore function in other neurological populations with severe disability is gait rehabilitation using treadmill training. This approach allows for specific and repetitive practice of walking movement and can involve therapist or electromechanical assistance. There is preliminary evidence from two small, uncontrolled studies supporting the benefits of therapist-assisted treadmill training on walking, balance, fatigue, spasticity, muscle strength, and quality of life in patients with PPMS and SPMS. Nevertheless, therapist-assisted gait training can require up to three trainers per patient making it burdensome and inefficient in the clinical setting. The intensity of manual treadmill training is low (i.e., \<1.5 METs) based in part on the physical capacity and fitness level of the trainers, yet physiological adaptations for optimizing outcomes require moderate or vigorous intensity exercise.
Robotic-assisted gait training (RAGT) addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases. The G-EO System (Reha Technology AG: Olten, Switzerland) is a novel end-effector robotic gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback. Gait training using the G-EO System has been applied in patients with stroke, Multiple Sclerosis (MS), and cerebral palsy (CP). These studies have established safety and feasibility, and preliminary evidence for benefits on mobility and function. For example, two studies involving 4 weeks of G-EO training with conventional physical therapy in non-ambulatory subacute stroke patients reported improved gait, stair climbing ability, leg strength, and activities of daily living (ADL) compared to physical therapy alone. There is limited RAGT studies evaluating the impact of this type of training for individuals with PD. The potential focus on improved gait kinematics may be of particular benefit for PD patients who often struggle with maintain step length and initiation.
The logistic advantages and advanced training capabilities of the G-EO System, as well as the benefits reported in other populations, support this strategy as an effective rehabilitation tool for restoring and maintaining function in Parkinson's disease. This approach represents an opportunity for improving current clinical practices for patients with Parkinson's disease. If successful, this project will provide initial evidence for increasing patient access to the G-EO System, and this could be accomplished through "regional technology centers" using a rural health-delivery approach.
The purpose of this study is to investigate the implementation of a novel gait rehabilitation stimulus (G-EO System) that could advance current clinical practices. The goal is to establish the safety and feasibility of gait training using the G-EO System as well as investigating the impact on mobility, function, quality of life, and participatory outcomes.
Research Design: We propose a single-blinded, randomized trial of electromechanically-assisted gait training using the G-EO System in patients with Parkinson's disease with gait disability. Enrolled participants will be randomized to either conventional physical therapy (CPT) or CPT with G-EO training. Participants will complete baseline assessments on Day 1 and then be scheduled for the intervention phase of the study. Regardless of group allocation, each participant will receive 12 total visits scheduled ideally for twice a week for 6 weeks. Within one week of completing the 12th physical therapy visit, participants will repeat the outcome assessments (post-intervention timepoint). Participants will then be asked to return 30 days later for a final outcome assessment (one month follow-up timepoint).
Specific Aim 1 will establish the safety and feasibility of gait training using the G-EO System.
Specific Aim 2 will determine the efficacy of gait training using the G-EO System for improving mobility, function, and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe dyskinesia or severe on-off phenomenon
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CPT sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be provided using traditional over-ground walking. Additional strategies for home exercises, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided. Training will be administered 2 times per week for 40-60 minutes for six weeks.
Other: Conventional Physical Therapy Treatment
CPT-GEO sessions will involve a warm-up using a cycle ergometer or treadmill walking, stretching, progressive strength training exercises, and balance training. Gait training will be administered using end-effector gait training protocols (G-EO trainer). Training will be administered 2 times per week for 40-60 minutes for six weeks.
Device: G-EO End-Effector Gait Trainer · Other: Conventional Physical Therapy Treatment
The G-EO Gait Trainer uses distal fixation to promote a gait recovery by facilitating a controlled walking environment that includes an over-ground pattern and stair climbing. In addition, the device provides body position control to enable the patient to concentrate on the cyclical motion of walking without the fear of falling. Physical therapists can control different parameters of the gait cycle through computerized adjustments and the training setting can be manipulated to engage patients in active participation.
Therapists will use traditional methods of neurological rehabilitation for improved gait and balance. These approaches will include stretching, strengthening, therapeutic exercises, balance training, and over-ground walking
Comfortable Walking Speed (CWS)
Participants will be asked to walk over a 14-foot pressure mat that will capture their comfortable walking speed. Patients will be instructed to walk at their normal comfortable speed. Walking will begin 5 feet prior to the mat so that each individual walks across the mat at a consistent speed. Participants will pass over the mat 2 times and an average speed will be calculated. It will take 5 minutes to complete this test and will be performed first.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Fast Walking Speed (FWS)
Participants will be asked to walk over a 14-foot pressure mat that will capture their fast walking speed. Patients will be instructed to walk at their fastest speed while maintaining safe, accurate gait. Walking will begin 5 feet prior to the mat so that each individual walks across the mat at a consistent speed. Participants will pass over the mat 2 times and an average speed will be calculated. It will take 5 minutes to complete this test and will be performed second.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Six Minute Walk Test (6MWT)
Participants will be asked to walk for 6 minutes along a 30m track that is a flat surface and obstacle free. Subjects may stop and rest as often as needed. Researchers will record the distance traveled during the six minute time period.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Six Minute Walk Test Walking Speed (6MWT)
Average walking speed during the 6-Minute Walk Test was measured in meters per second (m/s). Change from baseline was calculated at post-intervention and one-month follow-up. Positive change scores indicate increased average walking speed and improved performance. This is not a scale score.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
The Five Times Sit to Stand Test
The test will quantify functional lower extremity strength. It provides insight into the coordination of functional strength for the accomplishment of transitioning from one posture to another. The participant is asked to safely rise from sitting in a chair to standing and then sit back down five times in a row without using their hands. This test will take about 5 minutes to administer.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Activities-Specific Balance Confidence Scale (ABC)
The Activities-specific Balance Confidence (ABC) Scale assesses self-reported confidence in maintaining balance while performing activities of daily living. The scale contains 16 items, with each item rated from 0 (no confidence) to 100 (complete confidence). The total ABC score is calculated as the average of the 16 item scores and ranges from 0 to 100. Higher scores indicate greater balance confidence and a better outcome; lower scores indicate less balance confidence and a worse outcome.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Mini-Balance Evaluation Systems Test (MiniBESTest) - Anticipatory Subscale
The Mini-Balance Evaluation Systems Test (MiniBESTest) is a performance-based measure of dynamic balance. The Anticipatory subscale assesses anticipatory postural adjustments during functional movement. Item scores are summed to produce a subscale score ranging from 0 to 6 points. Higher scores indicate better balance performance and lower scores indicate greater balance impairment.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Mini-Balance Evaluation Systems Test (MiniBESTest) - Reactive Postural Control Subscale
The Mini-Balance Evaluation Systems Test (MiniBESTest) is a performance-based measure of dynamic balance. The Reactive Postural Control subscale assesses the ability to recover balance following an external perturbation; examining the effectiveness of compensatory stepping response. Item scores are summed to produce a subscale score ranging from 0 to 6 points. Higher scores indicate better balance performance and lower scores indicate greater balance impairment.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Mini-Balance Evaluation Systems Test (MiniBESTest) - Sensory Orientation Subscale
The Mini-Balance Evaluation Systems Test (MiniBESTest) evaluates an individual's ability to maintain postural stability when sensory information is altered or conflicting. It assesses how effectively a person uses visual, vestibular, and somatosensory inputs to maintain balance under increasingly challenging conditions. Item scores are summed to produce a subscale score ranging from 0 to 6 points. Higher scores indicate better balance performance and lower scores indicate greater balance impairment.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Mini-Balance Evaluation Systems Test (MiniBESTest) - Dynamic Gait Subscale
The Mini-Balance Evaluation Systems Test (MiniBESTest) is a performance-based measure of dynamic balance. It evaluates an individual's ability to maintain balance while walking under increasingly complex and functionally relevant conditions. It assesses the capacity to adapt gait when confronted with environmental demands, dual-tasking, changes in speed, head movements, obstacle negotiation, and turning. Item scores are summed to produce a subscale score ranging from 0 to 10 points. Higher scores indicate better balance performance and lower scores indicate greater balance impairment.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Score
The Parkinson's Disease Questionnaire-39 (PDQ-39) is a 39-item, disease-specific questionnaire assessing health-related quality of life in individuals with Parkinson's disease. It includes eight domains: Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort. Each item is scored from 0 to 4, with higher scores indicating greater difficulty. Individual domain scores are calculated by summing item responses, dividing by the maximum possible domain score, and multiplying by 100. Each domain ranges from 0 to 100. The PDQ-39 Summary Index is calculated as the unweighted mean of the eight domain scores and ranges from 0 to 100. Lower scores indicate better health-related quality of life, while higher scores indicate worse health-related quality of life.
Time frame: Baseline, Post-Intervention (within 1 week after last therapy session), and 30 days after Post-intervention Visit
Participants were recruited through the IU Health Neuroscience Center. Recruitment primarily occurred through physicians specializing in the treatment and management of Parkinson's disease who identified and referred potentially eligible individuals. Physical therapists within the clinical setting also identified potential participants among individuals referred for rehabilitation. Additional recruitment occurred through word of mouth and participant referrals.
| Milestone | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Started | 9 | 6 |
| Completed | 8 | 5 |
| Not completed | 1 | 1 |
| Withdrew: Injury unrelated to study prior to intervention | 1 | 0 |
| Withdrew: Did not initiate assigned intervention | 0 | 1 |
Participants will be asked to walk over a 14-foot pressure mat that will capture their comfortable walking speed. Patients will be instructed to walk at their normal comfortable speed. Walking will begin 5 feet prior to the mat so that each individual walks across the mat at a consistent speed. Participants will pass over the mat 2 times and an average speed will be calculated. It will take 5 minutes to complete this test and will be performed first.
| Meters/second | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 0.980 ± 0.185 | 0.749 ± 0.235 |
| Post Intervention | 1.073 ± 0.098 | 0.922 ± 0.313 |
| 1 month Follow Up | 1.112 ± 0.191 | 0.870 ± 0.220 |
Participants will be asked to walk over a 14-foot pressure mat that will capture their fast walking speed. Patients will be instructed to walk at their fastest speed while maintaining safe, accurate gait. Walking will begin 5 feet prior to the mat so that each individual walks across the mat at a consistent speed. Participants will pass over the mat 2 times and an average speed will be calculated. It will take 5 minutes to complete this test and will be performed second.
| Meters/second | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 1.398 ± 0.142 | 1.048 ± 0.399 |
| Post Intervention | 1.520 ± 0.157 | 1.340 ± 0.322 |
| 1 month Follow Up | 1.481 ± 0.187 | 1.267 ± 0.281 |
Participants will be asked to walk for 6 minutes along a 30m track that is a flat surface and obstacle free. Subjects may stop and rest as often as needed. Researchers will record the distance traveled during the six minute time period.
| meters | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 416.70 ± 89.00 | 292.57 ± 170.98 |
| Post Intervention | 489.38 ± 44.98 | 356.18 ± 89.40 |
| 1 month Follow Up | 473.40 ± 54.86 | 365.44 ± 136.49 |
Average walking speed during the 6-Minute Walk Test was measured in meters per second (m/s). Change from baseline was calculated at post-intervention and one-month follow-up. Positive change scores indicate increased average walking speed and improved performance. This is not a scale score.
| Meters/second | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 1.078 ± 0.224 | 0.808 ± 0.415 |
| Post Intervention | 0.136 ± 0.221 | 0.110 ± 0.275 |
| 1 month Follow Up | 0.174 ± 0.157 | 0.125 ± 0.261 |
The test will quantify functional lower extremity strength. It provides insight into the coordination of functional strength for the accomplishment of transitioning from one posture to another. The participant is asked to safely rise from sitting in a chair to standing and then sit back down five times in a row without using their hands. This test will take about 5 minutes to administer.
| Seconds | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 12.97 ± 1.37 | 19.16 ± 5.25 |
| Post Intervention | 11.36 ± 1.80 | 17.17 ± 4.19 |
| 1 month Follow Up | 12.20 ± 2.14 | 17.84 ± 2.42 |
The Activities-specific Balance Confidence (ABC) Scale assesses self-reported confidence in maintaining balance while performing activities of daily living. The scale contains 16 items, with each item rated from 0 (no confidence) to 100 (complete confidence). The total ABC score is calculated as the average of the 16 item scores and ranges from 0 to 100. Higher scores indicate greater balance confidence and a better outcome; lower scores indicate less balance confidence and a worse outcome.
| Scores on a Scale | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 76.0 ± 9.8 | 73.2 ± 23.0 |
| Post Intervention | 75.6 ± 7.7 | 76.4 ± 25.8 |
| 1 month Follow Up | 70.7 ± 10.9 | 78.5 ± 24.4 |
The Mini-Balance Evaluation Systems Test (MiniBESTest) is a performance-based measure of dynamic balance. The Anticipatory subscale assesses anticipatory postural adjustments during functional movement. Item scores are summed to produce a subscale score ranging from 0 to 6 points. Higher scores indicate better balance performance and lower scores indicate greater balance impairment.
| Score on a scale | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 4.25 ± 1.035 | 2.20 ± 1.789 |
| Post Intervention | 4.50 ± 0.756 | 3.40 ± 2.074 |
| 1 month Follow Up | 3.750 ± 1.909 | 3.00 ± 2.345 |
The Mini-Balance Evaluation Systems Test (MiniBESTest) is a performance-based measure of dynamic balance. The Reactive Postural Control subscale assesses the ability to recover balance following an external perturbation; examining the effectiveness of compensatory stepping response. Item scores are summed to produce a subscale score ranging from 0 to 6 points. Higher scores indicate better balance performance and lower scores indicate greater balance impairment.
| Score on a scale | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 3.750 ± 1.982 | 3.20 ± 2.049 |
| Post Intervention | 3.875 ± 0.991 | 2.800 ± 1.789 |
| 1 month Follow Up | 3.375 ± 1.847 | 1.800 ± 1.643 |
The Mini-Balance Evaluation Systems Test (MiniBESTest) evaluates an individual's ability to maintain postural stability when sensory information is altered or conflicting. It assesses how effectively a person uses visual, vestibular, and somatosensory inputs to maintain balance under increasingly challenging conditions. Item scores are summed to produce a subscale score ranging from 0 to 6 points. Higher scores indicate better balance performance and lower scores indicate greater balance impairment.
| Score on a scale | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 5.50 ± 0.756 | 4.00 ± 2.00 |
| Post Intervention | 5.875 ± 0.354 | 5.20 ± 1.304 |
| 1 month Follow Up | 5.00 ± 2.138 | 3.20 ± 2.950 |
The Mini-Balance Evaluation Systems Test (MiniBESTest) is a performance-based measure of dynamic balance. It evaluates an individual's ability to maintain balance while walking under increasingly complex and functionally relevant conditions. It assesses the capacity to adapt gait when confronted with environmental demands, dual-tasking, changes in speed, head movements, obstacle negotiation, and turning. Item scores are summed to produce a subscale score ranging from 0 to 10 points. Higher scores indicate better balance performance and lower scores indicate greater balance impairment.
| Score on a scale | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 7.50 ± 1.773 | 5.60 ± 3.209 |
| Post Intervention | 8.50 ± 1.069 | 7.20 ± 2.168 |
| 1 month Follow Up | 7.875 ± 3.482 | 5.20 ± 3.834 |
The Parkinson's Disease Questionnaire-39 (PDQ-39) is a 39-item, disease-specific questionnaire assessing health-related quality of life in individuals with Parkinson's disease. It includes eight domains: Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort. Each item is scored from 0 to 4, with higher scores indicating greater difficulty. Individual domain scores are calculated by summing item responses, dividing by the maximum possible domain score, and multiplying by 100. Each domain ranges from 0 to 100. The PDQ-39 Summary Index is calculated as the unweighted mean of the eight domain scores and ranges from 0 to 100. Lower scores indicate better health-related quality of life, while higher scores indicate worse health-related quality of life.
| Units on a scale | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) |
|---|---|---|
| Baseline | 25.05 ± 8.39 | 30.08 ± 17.07 |
| Post Intervention | 25.59 ± 11.29 | 25.08 ± 13.96 |
| 1 month Follow Up | 26.68 ± 9.14 | 14.06 ± 5.51 |
Collected over Adverse events were monitored throughout the 6-week intervention period and through the one-month follow-up assessment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Conventional Physical Therapy (CPT) Group | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) |
| Age, Continuous(years) | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) | Total |
|---|---|---|---|
| Mean | 76 (68 to 81) | 66 (50 to 75) | 70 (50 to 81) |
| Sex: Female, Male(Participants) | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 7 | 4 | 11 |
| Race and Ethnicity Not Collected(Participants) | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| 10 Meter Walk Test(Meters/second) | Conventional Physical Therapy (CPT) Group | Conventional Physical Therapy (CPT) Group With G-EO Training (CPT-GEO) | Total |
|---|---|---|---|
| Comfortable Walking Speed | 0.980 ± .185 | 0.749 ± 0.235 | 0.891 ± 0.228 |
| Fast Walking Speed | 1.398 ± 0.142 | 1.048 ± 0.399 | 1.264 ± 0.310 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — It is not determined at this time.
Ran from Jan 2022 to primary completion in Aug 2025, 43 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.